O	0	10	Evaluation
O	11	13	of
B-intervention	14	18	oral
I-intervention	19	23	care
O	24	26	to
O	27	34	prevent
B-condition	35	39	oral
I-condition	40	49	mucositis
O	50	52	in
O	53	61	estrogen
O	62	70	receptor
O	70	71	-
O	71	79	positive
O	80	90	metastatic
O	91	97	breast
O	98	104	cancer
O	105	113	patients
O	114	121	treated
O	122	126	with
O	127	137	everolimus
O	138	139	(
O	139	143	Oral
O	144	148	Care
O	148	149	-
O	149	151	BC
O	151	152	)
O	152	153	:
O	154	164	randomized
O	165	175	controlled
O	176	181	phase
O	182	185	III
O	186	191	trial
O	191	192	.

O	193	197	This
O	198	200	is
O	201	202	a
O	203	213	randomized
O	213	214	,
O	215	220	multi
O	220	221	-
O	221	227	center
O	227	228	,
O	229	233	open
O	233	234	-
O	234	239	label
O	239	240	,
O	241	246	phase
O	247	250	III
O	251	256	study
O	257	259	to
O	260	268	evaluate
O	269	272	the
O	273	281	efficacy
O	282	284	of
O	285	297	professional
O	298	302	oral
O	303	307	care
O	308	310	in
O	311	321	preventing
O	322	326	oral
O	327	336	mucositis
O	337	344	induced
O	345	347	by
O	348	358	everolimus
O	359	361	in
B-eligibility	362	376	postmenopausal
I-eligibility	377	385	estrogen
I-eligibility	386	394	receptor
I-eligibility	394	395	-
I-eligibility	395	403	positive
I-eligibility	404	414	metastatic
I-eligibility	415	421	breast
I-eligibility	422	428	cancer
O	428	429	.

O	430	438	Patients
O	439	443	will
O	444	446	be
O	447	457	randomized
O	458	462	into
O	463	475	professional
O	476	480	oral
O	481	485	care
O	486	489	and
B-control	490	497	control
O	498	504	groups
O	505	506	(
O	506	507	1
O	507	508	:
O	508	509	1
O	510	515	ratio
O	515	516	)
O	516	517	.

O	518	521	All
O	522	530	patients
O	531	535	will
O	536	543	receive
O	544	554	everolimus
O	555	559	with
O	560	570	exemestane
O	571	574	and
O	575	579	will
O	580	588	continue
O	589	599	everolimus
O	600	605	until
O	606	613	disease
O	614	625	progression
O	625	626	.

O	627	629	In
O	630	633	the
O	634	646	professional
O	647	651	oral
O	652	656	care
O	657	662	group
O	662	663	,
O	664	672	patients
O	673	677	will
O	678	685	receive
O	686	691	teeth
O	692	699	surface
O	700	708	cleaning
O	708	709	,
O	710	717	scaling
O	718	721	and
O	722	728	tongue
O	729	737	cleaning
O	738	744	before
O	745	753	starting
O	754	764	everolimus
O	764	765	,
O	766	769	and
O	770	774	will
O	775	783	continue
O	784	786	to
O	787	794	receive
O	795	807	professional
O	808	812	oral
O	813	817	care
O	818	824	weekly
O	825	829	from
O	830	834	oral
O	835	843	surgeons
O	844	854	throughout
O	855	858	the
O	859	860	8
O	861	865	week
O	866	875	treatment
O	875	876	.

O	877	879	In
O	880	883	the
O	884	891	control
O	892	897	group
O	897	898	,
O	899	907	patients
O	908	912	will
O	913	918	brush
O	919	924	their
O	925	928	own
O	929	934	teeth
O	935	938	and
O	939	945	gargle
O	946	950	with
O	951	952	0
O	952	953	.
O	953	954	9
O	954	955	%
O	956	962	sodium
O	963	971	chloride
O	972	980	solution
O	981	983	or
O	984	989	water
O	989	990	.

O	991	994	The
O	995	1002	primary
O	1003	1011	endpoint
O	1012	1014	is
O	1015	1018	the
B-outcome-Measure	1019	1028	incidence
I-outcome-Measure	1029	1031	of
I-outcome-Measure	1032	1035	all
I-outcome-Measure	1036	1042	grades
I-outcome-Measure	1043	1045	of
I-outcome-Measure	1046	1050	oral
I-outcome-Measure	1051	1060	mucositis
O	1060	1061	.

O	1062	1068	Target
O	1069	1076	accrual
O	1077	1079	is
B-total-participants	1080	1083	200
O	1084	1092	patients
O	1093	1097	with
O	1098	1099	a
O	1100	1103	two
O	1103	1104	-
O	1104	1109	sided
O	1110	1114	type
O	1115	1116	I
O	1117	1122	error
O	1123	1127	rate
O	1128	1130	of
O	1131	1132	5
O	1132	1133	%
O	1134	1137	and
O	1138	1140	80
O	1140	1141	%
O	1142	1147	power
O	1148	1150	to
O	1151	1157	detect
O	1158	1160	25
O	1160	1161	%
O	1162	1166	risk
O	1167	1176	reduction
O	1176	1177	.
